Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 23;218(1):e20201214. doi: 10.1084/jem.20201214

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Nishimura et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 4. — Establishment of controller status by successive cART therapy for 8 wk beginning at week 2 PI and combination bNAb treatment commencing on week 9 PI in rhesus macaques inoculated with SHIV_AD8-EO. (A) Six rhesus macaques were inoculated i.r. with 1,000 TCID₅₀ of SHIV_AD8-EO and initially received daily cART therapy for 8 wk beginning at week 2 PI (red bar) and were then administered combination 10–1074 plus 3BNC117 bNAbs (10 mg/kg each) at weeks 9, 11, and 13 PI (blue arrows). (B–G) Plasma virus loads in three controller (B–D) and three progressor (E–G) macaques are shown. Red arrows indicate the times of the anti-CD8α–depleting mAb MT807R1 infusion.